Norwegian Stoma Trial

NCT ID: NCT05243771

Last Updated: 2023-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Norwegian Stoma Trial is an open-label multicenter trial investigating the use of stomas, both diveriting and permanent, in the surgical treatment of rectal cancer. The objective is to compare the chosen strategy to surgical complications, health realted quality of life and length of stay.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this national, multicenter study the study group will investigate whether patients with rectal adenocarcinoma undergoing a resection with an anastomosis will benefit from a diverting stoma or not, by studying how choice of surgery affects complications. In addition the study group will investigate complication rates and HRQoL among patients receiving a permanent colostomy and compare this to patients who have received an anastomosis. The investigators know that there are different approaches to the use of stomas (both permanent and diverting) between different hospitals. The investigators aim to discover potential differences in complication rates, length of stay and HRQoL among these patients and compare this to the chosen strategy. Health related quality of life will be measured using the EORTC CR 29 and EORTC CR 30 questionnares. Bowel function will also be monitored using the LARS (low anterior resection syndrome) score.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer Ileostomy; Complications Quality of Life Complication,Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rectal resection with diverting stoma

Patients operated for rectal cancer with rectal resection and diverting stoma.

Rectal resection with diverting stoma

Intervention Type PROCEDURE

Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created

Rectal resection without diverting stoma

Patients operated for rectal cancer with rectal resection without diverting stoma.

Rectal resection without diverting stoma

Intervention Type PROCEDURE

Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created

Rectal resection with primary colostomy

Patients operated for rectal cancer with rectal resection with primary colostomy.

Rectal resection with permanent colostomy

Intervention Type PROCEDURE

Patients in this group will receive a rectal resection and a permanent colostomy will be created

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rectal resection with diverting stoma

Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created

Intervention Type PROCEDURE

Rectal resection without diverting stoma

Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created

Intervention Type PROCEDURE

Rectal resection with permanent colostomy

Patients in this group will receive a rectal resection and a permanent colostomy will be created

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older
* Verified rectal adenocarcinoma by biopsy
* Tumor located in the rectum with lower border of the tumor located 15 cm or less from the anal verge.
* Given informed consent

Exclusion Criteria

* Advanced tumor stage requiring exenterative surgery beyond a convetional APR or TME.
* Stage IV disease
* Synchronous colon cancer necessitating a total colectomy
* Other concomitant disease(s) which will complicate participation.
* Unwillingness to give informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Haukeland University Hospital

OTHER

Sponsor Role collaborator

University Hospital of North Norway

OTHER

Sponsor Role collaborator

Helse Nord-Trøndelag HF

OTHER

Sponsor Role collaborator

St. Olavs Hospital

OTHER

Sponsor Role collaborator

Alesund Hospital

OTHER

Sponsor Role collaborator

Helse Fonna

OTHER

Sponsor Role collaborator

Helse Stavanger HF

OTHER_GOV

Sponsor Role collaborator

Sorlandet Hospital HF

OTHER_GOV

Sponsor Role collaborator

Sykehuset Telemark

OTHER_GOV

Sponsor Role collaborator

Vestre Viken Hospital Trust

OTHER

Sponsor Role collaborator

Asker & Baerum Hospital

OTHER

Sponsor Role collaborator

Ullevaal University Hospital

OTHER

Sponsor Role collaborator

Oslo University Hospital

OTHER

Sponsor Role collaborator

Ostfold Hospital Trust

OTHER

Sponsor Role collaborator

University Hospital, Akershus

OTHER

Sponsor Role collaborator

Hamar Hospital

UNKNOWN

Sponsor Role collaborator

Gjøvik Hospital

UNKNOWN

Sponsor Role collaborator

Bodø Hospital

UNKNOWN

Sponsor Role collaborator

The Hospital of Vestfold

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lars Thomas

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lars Thomas Seeberg, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

The Hospital of Vestfold

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Asker og Baerum Hospital

Bærums verk, Gjettum, Norway

Site Status RECRUITING

Østfold Hospital Trust

Sarpsborg, Grålum, Norway

Site Status RECRUITING

Akershus University Hospital

Oslo, Lørenskog, Norway

Site Status RECRUITING

Ålesund Hospital

Ålesund, , Norway

Site Status RECRUITING

Haukeland University Hospital

Bergen, , Norway

Site Status RECRUITING

Bodø Hospital

Bodø, , Norway

Site Status RECRUITING

Vestre Viken Hospital Trust

Drammen, , Norway

Site Status RECRUITING

Gjøvik Hospital

Gjøvik, , Norway

Site Status RECRUITING

Hamar Hospital

Hamar, , Norway

Site Status RECRUITING

Helse Fonna

Haugesund, , Norway

Site Status RECRUITING

Sorlandet Hospital HF

Kristiansand, , Norway

Site Status RECRUITING

Helse Nord-Trøndelag HF

Levanger, , Norway

Site Status RECRUITING

Ullevaal University Hospital

Oslo, , Norway

Site Status RECRUITING

Sykehuset Telemark

Skien, , Norway

Site Status RECRUITING

Helse Stavanger HF

Stavanger, , Norway

Site Status RECRUITING

University Hospital of North Norway

Tromsø, , Norway

Site Status RECRUITING

St. Olavs Hospital

Trondheim, , Norway

Site Status RECRUITING

Vestfold Hospital Trust

Tønsberg, , Norway

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Norway

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lars Thomas Seeberg, MD, PhD

Role: CONTACT

+4733342000

Lars Grønvold, MD

Role: CONTACT

+4733342000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mathias Irgens, MD

Role: primary

Silje Sanengen, MD

Role: primary

Thomas Heggelund, MD

Role: primary

Thomas Nygaard, MD

Role: primary

Håvard Forsmo, MD, PhD

Role: primary

Kåre Nordland, MD

Role: primary

Johan Bondi, MD, PhD

Role: primary

Alexander Frodahl, MD

Role: primary

Jan Lambrecht, MD, PhD

Role: primary

Håvard Thorsen, MD

Role: primary

Martin Bøhler, MD

Role: primary

Eivor Laugsand, MD, PhD

Role: primary

Usman Saeed, MD

Role: primary

Silje Holte, MD

Role: primary

Ragnar Herikstad, MD

Role: primary

Martin Hagve, MD

Role: primary

Tore Stornes, MD, PhD

Role: primary

Lars Grønvold, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21/05179

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Scandinavian Diverticulitis Trial
NCT01047462 COMPLETED NA